Associated Papers
The equilibrium between two quaternary assembly states determines the activity of SPOP and its cancer mutants.
Cuneo MJ et al.
Biorxiv : the Preprint Server for Biology, 2025
SPOP point mutations regulate substrate preference and affect its function.
Deng Y et al.
Cell Death & Disease, 2024
Reduction of oligomer size modulates the competition between cluster formation and phase separation of the tumor suppressor SPOP.
Sabri N et al.
The Journal of Biological Chemistry, 2023
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.
Cavalcante L et al.
Jco Precision Oncology, 2023
Higher-order SPOP assembly reveals a basis for cancer mutant dysregulation.
Cuneo MJ et al.
Molecular Cell, 2023
Hidden tricks in MATH: Hypermorphic mutations in SPOP tumor suppressor explained by cryo-EM.
Orme JJ et al.
Molecular Cell, 2023
SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.
Gao K et al.
Cell Death and Differentiation, 2023
SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF.
Feng K et al.
Cell & Bioscience, 2022
Molecular Profile of Advanced Cutaneous Squamous Cell Carcinoma.
Jones J et al.
The Journal of Clinical and Aesthetic Dermatology, 2021
Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.
Fan Y et al.
Molecular Oncology, 2020
32478891 (PubMed )
Supplement: MOL2-14-1731-s002.xlsx › Sheet1
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_6.xlsx › Drivers-not-HR-HLA-A-B-only
Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D et al.
The Journal of Pathology, 2018
29604063 (PubMed )
Supplement: PATH-245-283-s020.xlsx › Figure.2.Drivers.Edited
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
Janouskova H et al.
Nature Medicine, 2017
Next-Generation Sequencing.
Le Gallo M et al.
Advances in Experimental Medicine and Biology, 2017
Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover.
Zhang P et al.
Cell Death & Disease, 2015
Low-grade serous carcinomas of the ovary contain very few point mutations.
Jones S et al.
The Journal of Pathology, 2012
Select a paper to view details